Effectiveness of Finerenone in Slowing Chronic Kidney Disease Progression After Hospitalization for Heart Failure: A FIDELITY Subgroup Analysis
Authors' conclusion
Treatment with finerenone is associated with clinically meaningful attenuation of CKD progression in people with CKD and T2D before HHF, and persists post-HHF
Study context
- Population
- Adults with chronic kidney disease (CKD) and T2D on optimized renin-angiotensin system inhibitor treatment who were hospitalised for HF between 4 months post randomization and study end
- Comparison
- Finerenone vs placebo
- Primary endpoint
- Change in chronic eGFR slope (creatinine-based eGFR) before and after HHF; eGFR values ±90 days from HHF excluded in primary analysis
Methodological detailsFIDELIO-DKD and FIGARO-DKD randomised trials, pooled phase 3 trials, randomized 1:1
- FIDELIO-DKD and FIGARO-DKD randomised trials
- Pooled phase 3 trials
- Randomized 1:1
Primary result
As reported in the abstract
Mean change in eGFR slope, pre-HHF and post-HHF
Finerenone vs PlaceboBetween-group difference, mL/min/1.73 m2/year (95% CI)
pre-HHF
2.68(0.87–4.49)
post-HHF
0.96(−0.99 to 2.91)
Original publication
Effectiveness of Finerenone in Slowing Chronic Kidney Disease Progression After Hospitalization for Heart Failure: A FIDELITY Subgroup Analysis. Eur J Heart Fail. Published 28 September 2026. doi:10.
Summarised from the published abstract; every number is checked against it